AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Akums Drugs and Pharmaceuticals submitted its Annual Secretarial Compliance Report for FY25 to BSE and NSE, as required under SEBI LODR Regulation 24A. The report was issued by secretarial auditor A.K. Nandwani & Associates (signed by Partner Kavita) and signed off by Company Secretary Dharamvir Malik on May 15-17, 2025. Two minor deviations were noted: (1) some designated employees sold shares within 6 months under the Insider Trading Code, for which the company sensitized relevant stakeholders; and (2) the Board composition fell short of Regulation 17(1)(b) requirements after Independent Director Mr. Nand Lal Kalra ceased effective February 5, 2025, with the company currently identifying a replacement director. All other compliance areas — secretarial standards, policies, website disclosures, director disqualification, related party transactions, insider trading, document preservation, performance evaluation — were marked compliant. No fines were imposed and no action was taken by SEBI or the stock exchanges during the review period. This is noted as the company's first year of listing.
This is a routine annual regulatory filing with no material financial impact on shareholders. The two minor compliance gaps (insider trading by some employees and a vacancy on the Board) are being addressed by management, so there is little reason for stock price movement.